Citi raised the firm’s price target on Arcturus Therapeutics (ARCT) to $49 from $47 and keeps a Buy rating on the shares. The firm believes the ARCT-032 Phase 2 readout in September offers a favorable risk/reward.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARCT:
- Optimistic Buy Rating for Arcturus Therapeutics Driven by Promising Developments in Cystic Fibrosis and COVID-19 Vaccine Programs
- Arcturus Therapeutics Reports Q2 2025 Earnings and Pipeline Progress
- Arcturus Therapeutics reports Q2 EPS (34c), consensus (87c)
- Is ARCT a Buy, Before Earnings?
- Private Markets: Canva draws attention as IPO candidate following Figma debut